Trial
NCT05109052
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Rochester
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
PXS-5505 and Atezolizumab and Bevacizumab
Why stopped
no accrual of eligible participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-13